2010 Clinical Trials Conditions Safety 
Cannabis Law Report
OCTOBER 9, 2021
A coalition of Pennsylvania lawmakers introduced a bill this week that’s meant to promote research into the therapeutic potential of psilocybin mushrooms for mental health conditions such as post-traumatic stress disorder (PTSD)—the latest example of how the psychedelics reform movement is gaining momentum. Led by Rep.
Cannabis Law Report
OCTOBER 29, 2019
ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement. Wakshlag, DVM, Ph.D.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
MARCH 18, 2021
Given the topical nature of the current trial and its relevance for public policy on medical cannabis, participants might have been biased to report positive effects regardless of condition. for the production of cannabis used in federally-regulated clinical trials. He has covered the legal cannabis industry since 2010.
Cannabis Law Report
JULY 28, 2021
Cepharanthine is on its way to establishing itself as a once per day, oral anti-cancer therapeutic with a well-established safety profile which will pave the way for an expedited clinical development pathway and future partnering opportunities with pharmaceutical companies. ” Next Steps. ” Next Steps. dcohen@pharmadrug.co.
Puff Puff Post
DECEMBER 28, 2018
With so many people affected by autism and incidence rates having increased by 119% between the years 2000 to 2010, it has gained the status of the quickest-growing developmental disability. They aren’t geared towards treating the condition specifically, and rather focus on reducing side-effects from the disorder like anxiety and insomnia.
Cannabis Law Report
NOVEMBER 24, 2021
Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access.
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. He is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs.
Expert insights. Personalized for you.
52 
Let's personalize your content